Article 03 Nov 2023 Baxalta's Antibody Patent Held Invalid Under Amgen's Enablement Standard By The Federal Circuit United States IP
Article 13 Sep 2021 Belcher Pharmaceuticals' Patent Held Unenforceable By The Federal Circuit United States IP